Spyre Therapeutics (SYRE) Institutional Ownership
13F filers reported holding 7.1% of Spyre Therapeutics (SYRE) shares as of Sep 30, 2026, across 92 filers.
- Held by 13F filers
- 7.1%
- Sep 30, 2026
- 13F filers
- 92
- quarter ended Sep 30, 2026
- 13F value
- $609.3M
- 6.7M shares
- Quarter's fund flow
- Mild accumulation
- 27 new · 11 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | King-Jones Heidy | See Remarks | Acquired · Option exercise | 28,933 | $14.50 | ↗ |
| Oct 1, 2026 | King-Jones Heidy | See Remarks | Disposed · Open-market sale | 400 | $89.24 | ↗ |
| Oct 1, 2026 | King-Jones Heidy | See Remarks | Disposed · Open-market sale | 16,605 | $90.35 | ↗ |
| Oct 1, 2026 | King-Jones Heidy | See Remarks | Disposed · Open-market sale | 7,228 | $91.35 | ↗ |
| Oct 1, 2026 | King-Jones Heidy | See Remarks | Disposed · Open-market sale | 2,100 | $92.70 | ↗ |
| Oct 1, 2026 | King-Jones Heidy | See Remarks | Disposed · Open-market sale | 2,600 | $93.46 | ↗ |
| Oct 1, 2026 | King-Jones Heidy | See Remarks | Disposed · Option exercise | 28,933Stock Option (Right to Buy) | — | ↗ |
| Oct 1, 2026 | Turtle Cameron | Chief Executive Officer | Disposed · Open-market sale | 600 | $89.14 | ↗ |
| Oct 1, 2026 | Turtle Cameron | Chief Executive Officer | Disposed · Open-market sale | 2,683 | $90.10 | ↗ |
| Oct 1, 2026 | Turtle Cameron | Chief Executive Officer | Disposed · Open-market sale | 2,638 | $91.49 | ↗ |
| Oct 1, 2026 | Turtle Cameron | Chief Executive Officer | Disposed · Open-market sale | 3,989 | $92.31 | ↗ |
| Oct 1, 2026 | Turtle Cameron | Chief Executive Officer | Disposed · Open-market sale | 4,990 | $93.37 | ↗ |
| Oct 1, 2026 | Turtle Cameron | Chief Executive Officer | Disposed · Open-market sale | 100 | $93.91 | ↗ |
| Oct 1, 2026 | Burrows Scott L | Chief Financial Officer | Acquired · Option exercise | 7,500 | $14.50 | ↗ |
| Oct 1, 2026 | Burrows Scott L | Chief Financial Officer | Disposed · Open-market sale | 600 | $89.07 | ↗ |
| Oct 1, 2026 | Burrows Scott L | Chief Financial Officer | Disposed · Open-market sale | 1,500 | $90.27 | ↗ |
| Oct 1, 2026 | Burrows Scott L | Chief Financial Officer | Disposed · Open-market sale | 2,100 | $91.92 | ↗ |
| Oct 1, 2026 | Burrows Scott L | Chief Financial Officer | Disposed · Open-market sale | 3,071 | $92.95 | ↗ |
| Oct 1, 2026 | Burrows Scott L | Chief Financial Officer | Disposed · Open-market sale | 229 | $93.57 | ↗ |
| Oct 1, 2026 | Burrows Scott L | Chief Financial Officer | Disposed · Option exercise | 7,500Stock Option (Right to Buy) | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Spyre Therapeutics do institutions hold?
13F filers reported holding 7.1% of Spyre Therapeutics' shares as of Sep 30, 2026, across 92 filers.
How many 13F filers hold Spyre Therapeutics?
Spyre Therapeutics was held by 92 13F filers as of Sep 30, 2026.
Not investment advice.

